• 作者： 王豐明; 蔡來誠; 張若南; 韓韶華; 曹汀
• 作者服務機構： 榮民總醫院外科部直腸外科; 醫學研究部臨床免疫研究室; 生物技術開發中心
• 中文摘要： 以固態相放射免疫分析法測定101位大腸直腸腺癌病人，109位其他癌症患者包括肺癌、乳癌、胃癌、脾臟癌及肝癌
  及20位吸煙，另20位不吸煙正常人血中CA19-9抗原濃度。在40個正常人血中CA19-9含量僅一個超過正常最高值(37.6
  U/ml)。吸煙(14.4±9.0U/ml)及不吸煙(16.0±10.2 U/ml)之平均含量無明顯差異。在腸癌患者血中CA19-9之平均含
  量在Dukes B期(P＜0.05)及Dukes C 及 D 期 (P＜0.001)均比正常組顯著升高。其他癌症如胃癌、肺癌及肝癌亦明顯升
  高，特別是脾臟癌最為顯著(p＜0.0001)。在腸癌各期病人血中CEA與 CA19-9含量均隨病況加重而逐漸升高，且趨勢
  相似。在局限性腸癌血中CA19-9之陽性率為18.6%，而轉移性腸癌為50%，然CA19-9與CEA之含量並無任何關聯(
  相關係數r=0.125)。雖然CA19-9試驗之敏感度(26.4%)比CEA試驗之敏感度(51.7%)為低，但前者特異性(97.5%)
  ，比後者特異性度(87.5%)為佳。本研究結果認為癌標誌CA19-9抗原可作為腸癌手術後追?及診斷腸癌是否復發之另
  一有用標誌。
  檔
• 英文摘要： The concentration of serum CA19-9 in 101 patients with colorectal adenocarcinoma (CRC), and109 patients with carcinomas of lung, breast, stomach and pancreas and hepatoma, and 40 normal healthycontrols including an equal number of smokers and nonsmokers were determined by solid phase radioim-munoassay of CA19-9 assay kits (Centocor). Of the normal sera, only 1 out of 40 (2.5%) was over 37.6U/ml. No significant difference of CA19-9 levels was found between smokers(14.4±9.0 U/ml) and non-smokers (16.0±10.2 U/ml) of normal control. In patients sera, the mean value of CA19-9 levels was signi-ficantly higher in patients with Dukes B (P＜0.05)and in patients with Dukes C and D (P＜0.001)thanthe normal healthy controls (15.2±10.2 U/ml). Analysis of serum CEA concentrations has shown a similarresult in patients with all Dukes staged CRC. The CA19-9 levels was also significantly elevated in patientswith gastric carcinoma, lung carcinoma, hepatoma, and especially in patients with pancreatic carcinoma(P＜0.0001). The levels of CA19-9 elevated in 50% (22/44) of patients with advanced CRC while the ele-vation was 8 of 43(18.6%) patients with localized CRC. A comparison of CA19-9 and CEA assays showedno correlation (r＝0.125)between the two assays. Although the CA19-9 assay (26.4%) was less sensitivethan the CEA assay (51.7%), the specificity of CA19-9 assay (97.5%) was better than that of CEA assay(87.5%). Our results suggest that the tumor marker of CA19-9 antigen may be another useful criterium forthe diagnosis of the recurrence of CRC in short-term follow-up study.
• 中文關鍵字： CA19-9; carcinomas; colorectal adenocarcinoma (CRC); CEA.
• 英文關鍵字： --